Inovio Pharmaceuticals {NASDAQ: INO} rose 0.5% during trading hours, but then 2.5% after hours following publication of an RBC broker “outperform” note, based on their enthusiasm for Inovio’s treatment VGX-3100 for cervical pre-cancers.

.

Inovio Pharmaceuticals {NASDAQ: INO} rose 0.5% during trading hours, but then 2.5% after hours following publication of an RBC broker “outperform” note, based on their enthusiasm for Inovio’s treatment for cervical pre-cancers.

.

RBC analyst Matthew Eckler says VGX-3100 could become the first such non-surgical treatment, and if successful in trials, could have “big upside”.

RBC joins a group of half-dozen other firms with coverage of INO, all in the Buy column.

Messner has a price target of $11, implying 76% upside from today’s closing price.